Ca-4-methyl-2-oxo-valerate (α-ketoanalogue to leucine, Ca salt) 101 mg, Ca-3-methyl-2-oxo-butyrate (α-ketoanalogue to valine, Ca salt) 86 mg, Ca-2-oxo-3-phenylpropionate (α-ketoanalogue to phenylalanine, Ca salt) 68 mg, Ca-3-methyl-2-oxo-valerate (α-ketoanalogue to isoleucine, Ca salt) 67 mg, Ca-DL-2-hydroxy-4-(methylthio) butyrate (α-hydroxyanalogue to methionine, Ca salt) 59 mg, L-lysine acetate 105 mg, L-threonine 53 mg, L-histidine 38 mg, L-tyrosine 30 mg, L-tryptophan 23 mg
Indications/Uses
Prevention & therapy of damages due to faulty or deficient protein metabolism in chronic renal insufficiency in connection w/ limited protein in food of 40 g daily (for adults) ie, generally in patients w/ GFR <25 mL/min.
Regularly monitor serum Ca level. Ensure sufficient supply of cal. Allow a period of at least 2 hr to pass between intake of Anlovex & drugs that form sparingly soluble compd w/ Ca (eg, tetracyclines, ciprofloxacin & norfloxacin, Fe fluoride & estramustine-containing drugs). No experience has been made w/ administration during lactation.
May lead to pathological increases of serum Ca level or intensification w/ simultaneous administration of medicaments containing Ca (eg, acetolyte). Reduce possible administration of Al hydroxide due to improved uraemic symptoms during therapy. Not to be co-administered w/ drugs that form sparingly soluble compd w/ Ca (eg, tetracyclines, ciprofloxacin & norfloxacin, Fe fluoride & estramustine-containing drugs). Increased susceptibility towards heart/cardiac-active glycosides & hence risk of arrhythmia w/ the rise of blood Ca conc.
Sign Out
